Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
Alternative Names: ARRY-162; ARRY-438162; Balimek; MEK-162; MEKTOVI; ONO-7703; PF-06811462Latest Information Update: 03 Jan 2025
Price :
$50 *
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Childrens Hospital Los Angeles; Dana-Farber Cancer Institute; German Cancer Research Center; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck KGaA; National Cancer Institute (USA); Novartis; Ono Pharmaceutical; Pfizer; Pierre Fabre; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Swiss Group for Clinical Cancer Research; University Health Network; University of Heidelberg; University of Pittsburgh
- Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Halogenated hydrocarbons; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
- Preregistration Thyroid cancer
- Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II Brain metastases; Glioma; Haematological malignancies; Multiple myeloma; Neurofibromatosis 1; Solid tumours
- Phase I/II Acute myeloid leukaemia; Biliary cancer; Cancer; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Pancreatic cancer; Triple negative breast cancer
- No development reported Uveal melanoma
- Discontinued Rheumatoid arthritis
Most Recent Events
- 03 Jan 2025 Updated efficacy and adverse event data from the phase III PHAROS trial in Non-small cell lung cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 14 Sep 2024 Efficacy and adverse events data from the phase II PHAROS trial in Non-small cell lung cancer released by Pfizer
- 07 Sep 2024 Updated adverse events data from the phase II PHAROS trial in Non-small cell lung cancer presented at the 25th World Conference on Lung Cancer (WCLC-2024 )